These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1087 related items for PubMed ID: 18991188

  • 1. Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity.
    Kuryliszyn-Moskal A, Ciolkiewicz M, Klimiuk PA, Sierakowski S.
    Scand J Rheumatol; 2009; 38(1):38-45. PubMed ID: 18991188
    [Abstract] [Full Text] [Related]

  • 2. Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus.
    Kuryliszyn-Moskal A, Klimiuk PA, Ciolkiewicz M, Sierakowski S.
    J Rheumatol; 2008 Jul; 35(7):1307-13. PubMed ID: 18484695
    [Abstract] [Full Text] [Related]

  • 3. Vascular endothelial growth factor in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities.
    Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Ciołkiewicz M.
    Arch Immunol Ther Exp (Warsz); 2007 Jul; 55(3):179-85. PubMed ID: 17557150
    [Abstract] [Full Text] [Related]

  • 4. Analysis of correlations between selected endothelial cell activation markers, disease activity, and nailfold capillaroscopy microvascular changes in systemic lupus erythematosus patients.
    Ciołkiewicz M, Kuryliszyn-Moskal A, Klimiuk PA.
    Clin Rheumatol; 2010 Feb; 29(2):175-80. PubMed ID: 19907914
    [Abstract] [Full Text] [Related]

  • 5. Circulating endothelial cells, endothelial apoptosis and soluble markers of endothelial dysfunction in patients with systemic lupus erythematosus-related vasculitis.
    Kluz J, Kopeć W, Jakobsche-Policht U, Adamiec R.
    Int Angiol; 2009 Jun; 28(3):192-201. PubMed ID: 19506538
    [Abstract] [Full Text] [Related]

  • 6. Assessment of serum vascular endothelial growth factor and nail fold capillaroscopy changes in systemic lupus erythematosus with and without cutaneous manifestations.
    Moneib HA, Salem SA, Aly DG, Khedr HT, Wafaey HA, Hassan HE.
    J Dermatol; 2012 Jan; 39(1):52-7. PubMed ID: 21950586
    [Abstract] [Full Text] [Related]

  • 7. Serum thrombomodulin in systemic lupus erythematosus and juvenile idiopathic arthritis.
    el-Gamal YM, Heshmat NM, el-Kerdany TH, Fawzy AF.
    Pediatr Allergy Immunol; 2004 Jun; 15(3):270-7. PubMed ID: 15209962
    [Abstract] [Full Text] [Related]

  • 8. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
    Mahmoud RA, El-Gendi HI, Ahmed HH.
    Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers.
    Frijns R, Fijnheer R, Schiel A, Donders R, Sixma J, Derksen R.
    J Rheumatol; 2001 Mar; 28(3):514-9. PubMed ID: 11296951
    [Abstract] [Full Text] [Related]

  • 14. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.
    Wais T, Fierz W, Stoll T, Villiger PM.
    J Rheumatol; 2003 Oct; 30(10):2133-9. PubMed ID: 14528506
    [Abstract] [Full Text] [Related]

  • 15. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.
    Hao JH, Ye DQ, Zhang GQ, Liu HH, Dai H, Huang F, Pan FM, Su H, Dong MX, Chen H, Wang Q, Zhang XJ.
    Arch Dermatol Res; 2006 Jan; 297(7):329-32. PubMed ID: 16328345
    [Abstract] [Full Text] [Related]

  • 16. Anti-endothelial cell autoantibodies and soluble markers of endothelial cell dysfunction in systemic lupus erythematosus.
    Constans J, Dupuy R, Blann AD, Resplandy F, Seigneur M, Renard M, Longy-Boursier M, Schaeverbeke T, Guérin V, Boisseau MR, Conri C.
    J Rheumatol; 2003 Sep; 30(9):1963-6. PubMed ID: 12966599
    [Abstract] [Full Text] [Related]

  • 17. The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus.
    Kümpers P, David S, Haubitz M, Hellpap J, Horn R, Bröcker V, Schiffer M, Haller H, Witte T.
    Ann Rheum Dis; 2009 Oct; 68(10):1638-43. PubMed ID: 18930996
    [Abstract] [Full Text] [Related]

  • 18. Association of Nail Dystrophy With Accrued Damage and Capillaroscopic Abnormalities in Systemic Lupus Erythematosus.
    Higuera V, Amezcua-Guerra LM, Montoya H, Massó F, Patlán M, Paez A, Varela E, Rodríguez-Galicia V, Silveira LH.
    J Clin Rheumatol; 2016 Jan; 22(1):13-8. PubMed ID: 26693621
    [Abstract] [Full Text] [Related]

  • 19. Nailfold capillaroscopic changes in patients with systemic lupus erythematosus: correlations with disease activity, skin manifestation and nephritis.
    Shenavandeh S, Habibi S.
    Lupus; 2017 Aug; 26(9):959-966. PubMed ID: 28056626
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities.
    Riccieri V, Rinaldi T, Spadaro A, Scrivo R, Ceccarelli F, Franco MD, Taccari E, Valesini G.
    Clin Rheumatol; 2003 May; 22(2):102-6. PubMed ID: 12740673
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.